ClinicalTrials.gg
RecruitingNCT07247136Updated Mar 5, 2026

Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System

An interventional study of Neuspera Implantable Sacral Neuromodulation System in Urinary Urge Incontinence, sponsored by Neuspera Medical, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Neuspera Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.

Planned enrollment
84th of 119
30 · median 75
Started
2025
with 6 others
No phase
72 of 135
10 open now
Primary completion
2026-11
later than 11 of 25 live
Registered
131st of 135
by date

Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 84th largest by planned enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2025, is one of 72 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 131st registered.

Urinary Incontinence, Urge

243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.

Browse Urinary Incontinence, Urge studies →

Open to participants now

19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Urinary Incontinence, Urge with a site in United States, or all of them as a file.
02

Study summary

Single-arm study conducted in participants for the treatment of urinary urge incontinence in patients who have failed, could not tolerate, or were not a candidate for more conservative treatments.

The objective of the study is to assess the effectiveness of 30-minutes daily therapeutic stimulation with the Neuspera System.

Read the detailed description

The study is intended to investigate the potential for controlling UUI symptoms with thirty minutes of stimulation per day.

Subjects will be enrolled in a single-arm study and followed for 6 months post implant. Subjects will undergo a trial stimulation period, followed by a permanent implant. If subjects do not receive appropriate benefits with the shorter duration of stimulation, they can increase the duration of stimulation anytime as needed. Subjects may also decrease stimulation after one month to 15 minutes per day if desired.

Up to 30 subjects will be implanted.

03

Conditions studied

  • Urinary Urge Incontinence
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female 22 years of age or older.
  • Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening baseline visit date.
  • Has failed, could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects), or not a good candidate for (as determined by treating physician) at least one (1) antimuscarinic or β3 adrenoceptor agonist medication.
  • Is willing and able to washout (at least five half-lives) from OAB medications for a period determined appropriate based on type of OAB medication prior to the baseline bladder diary and remain off OAB medications through the study duration OR must be willing to maintain medication through the study duration.
  • Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary.
  • Has a positive stimulation trial with a 50% reduction in UUI episodes.

Exclusion criteria

Exclusion Criteria:

  • Has a for the Neuspera SNM System per the device labeling.
  • Has a of >8%.
  • Has glucosuria.
  • Has diabetic neuropathy.
  • Has interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines, chronic pelvic pain, or recurrent symptomatic urinary tract infections.
  • Has skin, orthopedic, neurological, or hematological (bleeding disorder) or anatomical limitations that could prevent successful placement of the neurostimulator.
  • Has broken, blistered skin or compromised circulation in the area of the neurostimulator implant.
  • Has neurogenic bladder dysfunction such as traumatic or atraumatic myelopathy, multiple sclerosis, Parkinsonism, or history of cerebrovascular accident.
  • Has documented urinary retention within 6 months prior to the screening baseline visit date.
  • Has bladder outlet obstruction.
  • Is currently undergoing or has previously undergone pelvic irradiation.
  • Is a subject with a mechanical obstruction such as benign prostatic hypertrophy, urethral stricture, or cancer.
  • Has current grade 3 or 4 pelvic organ prolapse including cystocele, rectocele, enterocele, procidentia or vaginal vault prolapse.
  • Has received tibial nerve stimulation (TNS) in the past 3 months for the treatment of overactive bladder or unwilling to stay off TNS therapy for the study duration.
  • Has received treatment of urinary symptoms with any botulinum neurotoxin type-A (BoNT-A) agent in the past 6 months; (e.g. obotulinumtoxinA, Botox,® abobotulinumtoxinA, Dysport® IncobotulinumtoxinA, Xeomin®).
  • Is a woman who is pregnant or planning to become pregnant during this clinical study or is a woman of who is not using a medically acceptable method of . Women of child-bearing potential must undergo a pregnancy test, with clear negative result.
  • Has previously had SNM therapy.
  • Has active implantable medical devices such as neurostimulators, drug pumps, pacemakers, or internal defibrillators since compatibility has not been assessed.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Neuspera Implantable Sacral Nerve Stimulation System

    Implantation of the stimulator to assess effectiveness with shorter duration of stimulation

    Device: Neuspera Implantable Sacral Neuromodulation System

Interventions

  • DeviceNeuspera Implantable Sacral Neuromodulation System

    Stimulation of the Sacral Nerve

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint- Proportion of Subjects experiencing a device- and/or procedure-related AEs

    Proportion of Subjects experiencing a device- and/or procedure-related Adverse events

    Time frame: 6 months

  2. Primary Effectiveness Endpoint-Percentage of all implanted subjects who experience an improvement in UUI episodes.

    Percentage of all implanted subjects who experience an improvement in UUI episodes of at least 50% or more, relative to the number of UUI episodes at baseline.

    Time frame: 1, 3 and 6 months post implant

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 25, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247136
Lead sponsor
Neuspera Medical, Inc.
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Nov 19, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Mark Vollmer
Contact
mark.vollmer@neuspera.com
408-433-3839
Shital Patel
Contact
shital.patel@neuspera.com
323-528-1320
Jessica Reub, MD
principal investigator · Southern Urogynecology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion